Nykredit A/S’s Recursion Pharmaceuticals RXRX Stock Holding History

Nykredit A/S’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$19.8K	Buy	+5,395	New	+$18K	﹤0.01%	1736

Other funds holding RXRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Nykredit A/S's RXRX Position: Q2 2026 in Review

Nykredit A/S opened a new position in Recursion Pharmaceuticals (RXRX) in Q2 2026: 5,395 shares worth $19.8K. The stake represents ﹤0.01% of the portfolio and ranks #1736 among its holdings.

250 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

Nykredit A/S held 5,395 shares of Recursion Pharmaceuticals worth $19.8K as of Q2 2026.
Recursion Pharmaceuticals was a new Nykredit A/S position in Q2 2026.
Recursion Pharmaceuticals made up ﹤0.01% of Nykredit A/S's portfolio in Q2 2026, its #1736 holding.
250 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Nykredit A/S's 13F filing for Q2 2026, filed 13 Aug 2026.